Abstracts tagged "COVID-19"

Abstract Number: 0099 • ACR Convergence 2021
First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Kurt de Vlam¹, Jeroen Geldhof², Marie Truyens³, Joao Sabino⁴, Marc ferrante⁴, Jo Lambert³, Hilde lapeere³, Tom hillary⁴, an Van Laethem⁴, Triana Lobaton³, severine vermeire⁴, Barbara Neerinckx¹ and Patrick Verschueren⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²University Hospital Gent, Gent, Belgium, ³university hospital gent, gent, ⁴university hospitals leuven, leuven, ⁵University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
Abstract Number: 0119 • ACR Convergence 2021
Worsened Depression but Improved Fatigue Were the Main Impacts of Severe Lockdown in Non- COVID Infected Australian Fibromyalgia Patients
Benjamin Worcester¹, Emma Guymer² and Geoffrey Littlejohn², ¹Monash Health, Melbourne, Australia, ²Monash University, Melbourne, Australia
Background/Purpose: To gauge the impact of severe COVID-19 related lockdown restrictions on the mental and physical wellbeing of Australian fibromyalgia patients and their recovery following…
Abstract Number: 0618 • ACR Convergence 2021
Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
Alice Fike¹, Omer Pamuk², Yiming Luo³, Jun Chu⁴, Yanira Ruiz-Perdomo³, Sarfaraz Hasni³, Pravitt Gourh³ and James Katz⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²NIH/NIAMS, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The longitudinal experience of COVID-19 illness in patients with rheumatic diseases is emerging. Reports from the general population have described post-acute sequelae of SARS-CoV-2…
Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Caroline Diorio¹, Rawan Shraim¹, Laura Vella¹, Josephine Giles², Amy Baxter², Derek Oldridge², Scott Canna¹, Sarah Henrickson¹, Kevin Mcnerney¹, Frances Balamuth¹, Chakkapong Burudpakdee¹, Jessica Lee¹, Tomas Leng¹, Alvin Farrell¹, Michele Lambert¹, Kathleen Sullivan¹, John Wherry³, David Teachey¹, Hamid Bassiri¹ and Edward Behrens¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³UPenn, Philadelphia, PA
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…
Abstract Number: 1278 • ACR Convergence 2021
Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
Ariana González-Meléndez¹ and Luis Vilá², ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: The coronavirus disease 2019 (COVID-19) pandemic is of particular concern for people with autoimmune rheumatic diseases and for those who are immunosuppressed given the…
Abstract Number: 1536 • ACR Convergence 2021
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
Sara Tedeschi¹, Jack Ellrodt¹, Jacklyn Stratton¹, Leah Santacroce¹, Paulette Chandler¹, Ellen Gravallese² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
Abstract Number: 1555 • ACR Convergence 2021
Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
Ikwinder Kaur¹, Mohsin Mughal², Abdul Asbeutah³, Mili Kakadia², Reem Alhashemi⁴, Hasan Mirza⁵, Harjot Jagdey⁶, Rasha Alhashimi⁷, vishakha sirpal², Punit Jariwala² and Eugenio Capitle⁸, ¹Monmouth Medical Center, an affiliate of Rutgers health system, Long Branch, NJ, ²Monmouth Medical Center, Long Branch, NJ, ³University of Tennessee Health Science Center, Memphis, TN, ⁴Monmouth Medical Center, Long Branch, NJ, ⁵Berkshire Medical Center, Pittsfield, MA, ⁶BronxCare Hospital, Bronx, NY, ⁷BIDMC, Havard, Boston, MA, ⁸Rutgers New Jersey Medical School, New Brunswick, NJ
Background/Purpose: COVID-19 has been implicated in an exaggerated inflammatory response by activating both innate and adaptive immune responses. Rheumatic disease patients are a vulnerable population…
Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Kelly Gavigan¹, Esteban Rivera¹, Jeffrey Curtis², Shilpa Venkatachalam¹, Laura Stradford³, David Curtis¹ and William Nowell¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Nyack, NY
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 1938 • ACR Convergence 2021
A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions
Anurag Verma¹, Noah Tsao¹, Lauren Thomann², Yuk-Lam Ho², Rotonya Carr¹, Dana crawford³, Jimmy efird⁴, Jennifer Huffman², Adriana Hung⁵, Kerry Ivey², Sudha Iyengar³, Michael Levin⁶, Shiuh-Wen luoh⁷, Julie Lynch⁸, Pradeep Natarajan⁹, Saiju Pyarajan¹⁰, alexander Bick¹¹, Lauren Costa², Giulio Genovese¹², Richard Hauger¹³, Ravi madduri¹⁴, Gita Pathak¹⁵, Renato polimanti¹⁵, Benjamin Voight¹, Marijana Vujkovic¹, Maryam Zekavat¹⁵, Hongyu Zhao¹⁵, Marylyn Ritchie¹, Kyong-Mi Chang¹⁶, Kelly Cho², Juan casas², Phil Tsao¹⁷, J. Michael Gaziano², Christopher ODonnell², Scott Damrauer¹ and Katherine Liao¹⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Boston Healthcare System, Boston, MA, ³Case Western Reserve University, Cleveland, OH, ⁴DVAHCS, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Pennsylvania, Philadelphia, ⁷Oregon Health & Science University, Portland, ⁸VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Partners, Boston, ¹¹Vanderbilt University, Nashville, TN, ¹²Harvard Medical School, Boston, MA, ¹³University of California San Diego, San Diego, CA, ¹⁴Argon National Lab, Chicago, IL, ¹⁵Yale University, New Haven, CT, ¹⁶VA Philadelphia, Philadelphia, PA, ¹⁷VA Palo Alto, Palo Alto, CA, ¹⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…
Abstract Number: 0075 • ACR Convergence 2021
Endothelial Cell-activating Antibodies in COVID-19
Hui Shi¹, Yu Zuo², Sherwin Navaz², Alyssa Harbaugh², Claire Hoy², Alex Gandhi², Gautam Sule², Srilakshmi Yalavarthi², Kelsey Gockman², Jacqueline Madison², Jintao Wang², Melanie zuo², Yue Shi³, Michael Maile², Yogendra Kanthi² and Jason Knight², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Shanghai Sports School, Shanghai, China (People's Republic)
Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Jutta Richter⁵, Anne Regierer⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Ulf Müller-Ladner¹² and Christof Specker¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁶German Rheumatism Research Center, Berlin, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ¹³Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…
Abstract Number: 0146 • ACR Convergence 2021
Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
Akrithi Udupa¹, Catherine Sims², Poorva Apte², Megan Milne², Isaac Smith¹, D Ryan Anderson¹, Mithu Maheswaranathan², Jayanth Doss² and David Leverenz², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: The COVID-19 pandemic led to the rapid implementation of telehealth in rheumatology with unknown implications for medication toxicity lab monitoring. The purpose of this…
Abstract Number: 0629 • ACR Convergence 2021
Patient and Physician Satisfaction with Telemedicine Utilization for Delivery of Care in Patients with SLE – A Single Centre Experience
Tanmayee Bichile¹, Amanda Bembic², Susan Manzi¹ and Sonia Manocha¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Allgheny Health Network, Pittsburgh, PA
Background/Purpose: COVID 19 has forced the healthcare system to utilize telemedicine to provide dependable and timely care for patients with SLE. Telemedicine has been used…
Abstract Number: 0962 • ACR Convergence 2021
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Arielle Mendel¹, Marvin Fritzler², Yvan St.Pierre¹, Joyce Rauch³, Sasha Bernatsky³ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although several studies indicate that patients with COVID-19 produce antiphospholipid antibodies (aPL), it is unclear which aPL subtype predominates and whether aPL correlates with…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].